Northern Trust Corp Grows Stake in Certara, Inc. (NASDAQ:CERT)

Northern Trust Corp boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 14.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 877,010 shares of the company’s stock after acquiring an additional 108,038 shares during the quarter. Northern Trust Corp owned about 0.54% of Certara worth $9,340,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its holdings in Certara by 0.3% during the 4th quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company’s stock valued at $132,455,000 after buying an additional 38,068 shares during the period. Teacher Retirement System of Texas increased its position in Certara by 13.9% during the fourth quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company’s stock valued at $48,542,000 after acquiring an additional 557,348 shares during the last quarter. Massachusetts Financial Services Co. MA raised its stake in shares of Certara by 4.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company’s stock valued at $43,494,000 after acquiring an additional 182,042 shares during the period. Brown Brothers Harriman & Co. lifted its holdings in shares of Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock worth $40,668,000 after acquiring an additional 1,487,998 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Certara by 169.0% during the 4th quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock worth $21,248,000 after purchasing an additional 1,253,385 shares during the period. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have issued reports on the company. KeyCorp boosted their target price on Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. JMP Securities reiterated a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. Stephens reissued an “overweight” rating and set a $17.00 target price on shares of Certara in a research note on Thursday, February 27th. TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, William Blair reiterated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.67.

Certara Stock Performance

Shares of NASDAQ:CERT opened at $11.88 on Friday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -59.40, a price-to-earnings-growth ratio of 9.29 and a beta of 1.57. The firm has a 50 day moving average of $11.72 and a 200 day moving average of $11.73. Certara, Inc. has a 52 week low of $8.64 and a 52 week high of $17.76.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.10 by $0.04. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. During the same period in the previous year, the company posted $0.10 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. On average, sell-side analysts predict that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.